News & Insights | Antibody Engineering

This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibodies U.S. eBook: Post-Event Report 2023

Antibody Europe eBook: Post-Event Report 2023

Antibodies eBook: Antibody Discovery Technologies and Platforms

On-Demand Webcast: IgM Antibodies and Other Alternative Frameworks — Promise and Progress

Monoclonal Antibodies eBook: Design, Engineering, Characterization, Manufacturing, and Formulation

Antibody U.S. eBook: Engineering and Next Generation Therapeutics 2022 — Post-Event Report

Software Powering the Next Generation of Antibody R&D | Benchling

eBook: Antibody Discovery Technologies and Platforms

eBook: Human Antibody Repertoires

af

Antibody Engineering & Therapeutics 2021: The Rewind

Transforming Therapeutic Targets for Antibody Drug Discovery

Novel and Difficult Targets in Antibody Drug Discovery

Enhancing Therapeutic Index of Antibodies through Inducible Activation

REPORT: COVID-19 One Year On - Impacts on the Global Life Sciences Industry 2021

Antibody Engineering & Therapeutics Europe Virtual 2021: The Rewind

Antibody discovery is the biggest challenge in antibody therapeutics

REPORT: Antibody Engineering & Therapeutics State of the Industry 2021

Life Sciences Survey: COVID-19 Impacts One Year On

Human Monoclonal Antibodies for SARS-CoV-2

Quick Links